Scientists Find Genetic Switch That Revives Exhausted Cancer Fighting T Cells
Researchers discovered how to restore tumor-killing power in worn-out immune cells by switching off just two genes.
20 articles
Researchers discovered how to restore tumor-killing power in worn-out immune cells by switching off just two genes.
When tumors hide from killer T cells, they accidentally expose themselves to helper T cells that trigger a lethal iron-driven cell death process.
Redesigned immunotherapy injected into one tumor triggered complete cancer remission in 2 of 12 patients, with untreated tumors also disappearing.
Chinese researchers developed a breakthrough method to mass-produce powerful immune cells that hunt and destroy cancer tumors.
New research reveals how tumors reprogram neutrophils to produce CCL3, turning immune defenders into cancer allies.
A short pre-surgery course of pembrolizumab left zero relapses in colorectal cancer patients after 33 months โ reshaping treatment strategy.
A new imaging breakthrough reveals how immune cells target cancer with nanoscale precision, opening doors for better immunotherapy.
A protein called HOXD13 drives skin cancer growth and shields tumors from immune cells โ disabling it could unlock powerful new treatments.
McGill scientists boosted NK cell cancer-killing power using reversible drug treatment, targeting leukemia, glioblastoma, and triple-negative breast cancer.
Northwestern researchers dramatically boosted cancer vaccine effectiveness by simply repositioning one protein fragment on their nanovaccine.
Revolutionary CRISPR technique bypasses lab manufacturing by programming immune cells to fight cancer directly in the body.
MYC protein doesn't just fuel tumor growth โ it also repairs DNA damage from chemotherapy, revealing a key resistance mechanism.
A newly identified molecule called SLAMF6 exhausts cancer-fighting T cells from within โ and blocking it may revive failed immunotherapies.
Scientists discover how small cell lung cancer uses inflammation to become more aggressive and resistant to treatment.
Key biotech companies developing T cell engager therapies that redirect immune cells to fight cancer more effectively.
Disabling the NFIL3 protein prevents CAR T cell exhaustion, boosting tumor-fighting power in animal models of hard-to-treat cancers.
Breakthrough antibodies completely prevent EBV infection in lab models, offering hope against virus linked to cancer and chronic disease.
New research reveals how tumors communicate with immune cells to avoid detection, potentially leading to better biomarkers and treatments.
Single injection of engineered virus kills glioblastoma cells and activates immune system, extending patient survival in clinical trial.
Australian biotech company creates targeted treatment that attacks malignant plasma cells while sparing healthy ones in multiple myeloma patients.